CombiMatrix Closes $8.0 Million Underwritten Public Offering
24 Marzo 2016 - 8:00AM
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics
company specializing in DNA-based testing services for prenatal and
postnatal developmental disorders and pre-implantation genetic
screening services, today announced that it has closed its
previously announced firm commitment underwritten public offering
of 8,000 units of Series F convertible preferred stock and warrants
at a price to the public of $1,000 per unit for gross proceeds
of $8.0 million, prior to deducting underwriting discounts and
commissions and offering expenses payable by the Company.
Ladenburg Thalmann & Co. Inc., a subsidiary
of Ladenburg Thalmann Financial Services
Inc. (NYSEMKT:LTS), served as the sole bookrunning manager and
Aegis Capital Corp. served as lead manager on the
transaction.
Each unit consists of one share of Series F
convertible preferred stock, which is convertible into 258.397875
shares of common stock at a conversion price of $3.87 per
share, and 258.397875 warrants each to purchase one share of common
stock at an exercise price of $5.17 per share. In
total, the Series F convertible preferred stock is convertible into
2,067,183 shares of common stock, and the warrants are exercisable
for 2,067,183 shares of common stock. The Company will use
part of the proceeds from this offering to repurchase and retire
its Series E convertible preferred stock.
This offering shall be made only by means of a
prospectus. Copies of the final prospectus relating to this
offering may be obtained at the SEC's website
at http://www.sec.gov or by request by contacting
Ladenburg Thalmann & Co. Inc., 570 Lexington Ave, 11th Floor,
New York, NY 10022 or by email at
prospectus@ladenburg.com.
In connection with this offering, the Company
has filed a registration statement on Form S-1 that was declared
effective by the SEC on March 18, 2016. This
press release shall not constitute an offer to sell or the
solicitation of an offer to buy any of the securities described
herein, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About CombiMatrix
Corporation
CombiMatrix Corporation provides valuable
molecular diagnostic solutions and comprehensive clinical support
to foster the highest quality in patient care. CombiMatrix
specializes in prenatal diagnostics, miscarriage analysis for
recurrent pregnancy loss, pediatric genetics and pre-implantation
genetic screening, offering DNA-based testing for the detection of
genetic abnormalities beyond what can be identified through
traditional methodologies. CombiMatrix performs genetic testing
utilizing a variety of advanced cytogenomic techniques, including
chromosomal microarray, standardized and customized fluorescence in
situ hybridization (FISH) and high-resolution karyotyping.
CombiMatrix is dedicated to providing high-level clinical support
for healthcare professionals in order to help them incorporate the
results of complex genetic testing into patient-centered medical
decision making. Additional information about CombiMatrix is
available at www.combimatrix.com or by calling (800) 710-0624.
Safe Harbor Statement under the Private
Securities Litigation Reform Act of 1995
This press release contains forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995. These
statements are based upon our current expectations, speak only as
of the date hereof and are subject to change. All statements, other
than statements of historical fact included in this press release,
are forward-looking statements. Forward-looking statements can
often be identified by words such as "anticipates," "expects,"
"intends," "plans," "goal," "predicts," "believes," "seeks,"
"estimates," "may," "will," "should," "would," "could,"
"potential," "continue," "ongoing," similar expressions, and
variations or negatives of these words. These forward-looking
statements are not guarantees of future results and are subject to
risks, uncertainties and assumptions that could cause our actual
results to differ materially and adversely from those expressed in
any forward-looking statement. The risks and uncertainties referred
to above include, but are not limited to: our ability to
successfully expand the base of our customers and strategic
partners, add to the menu of our diagnostic tests, develop and
introduce new tests and related reports, expand and improve our
current suite of services, optimize the reimbursements received for
our microarray testing services, and increase operating margins by
improving overall productivity and expanding sales volumes; our
ability to successfully accelerate sales, steadily increase the
size of our customer rosters in both prenatal and developmental
genetic testing markets; our ability to attract and retain a
qualified sales force in wider geographies; our ability to ramp
production from our sales force and our strategic partners; rapid
technological change in our markets; changes in demand for our
future services; legislative, regulatory and competitive
developments; general economic conditions; and various other
factors. Further information on potential factors that could affect
our financial results is included in our Annual Report on Form
10-K, Quarterly Reports of Form 10-Q, and in other filings with
the Securities and Exchange Commission. We undertake no
obligation to revise or update publicly any forward-looking
statements for any reason, except as required by law.
|
|
|
|
|
|
|
|
|
|
Company Contact: |
|
|
|
|
|
|
|
|
Investor Relations Contact: |
Mark McDonough |
|
|
|
|
|
|
|
|
LHA |
President & CEO, CombiMatrix Corporation |
|
|
|
|
|
|
|
|
Jody Cain |
(949) 753-0624 |
|
|
|
|
|
|
|
|
(310) 691-7100 |
|
|
|
|
|
|
|
|
|
jcain@lhai.com |
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024